Trevogrumab clinical trials
Also written REGN1033.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses trevogrumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 2 |
| 2016 | 2 |
| 2019 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses trevogrumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationActive, not recruitingPhase 2Regeneron PharmaceuticalsNCT06299098Written as Trevogrumab-Part A
- Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult MenCompletedPhase 1Regeneron PharmaceuticalsNCT02943239Written as REGN1033
- Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body MyositisWithdrawnPhase 2Regeneron PharmaceuticalsNCT03710941Written as REGN2477+REGN1033
- Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy SubjectsCompletedPhase 1Regeneron PharmaceuticalsNCT02741739Written as REGN1033
- Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With SarcopeniaCompletedPhase 2Regeneron PharmaceuticalsNCT01963598Written as REGN1033 (SAR391786)
- Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)CompletedPhase 1Regeneron PharmaceuticalsNCT01910220Written as REGN1033 (SAR391786)
- Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)CompletedPhase 1Regeneron PharmaceuticalsNCT01720576Written as REGN1033 (SAR391786)
- A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)CompletedPhase 1Regeneron PharmaceuticalsNCT01507402Written as REGN1033(SAR391786)
Codes
What other systems call trevogrumab · ClinicalTrials.gg INT015620
- UNII (FDA) 87T4327873TREVOGRUMABConfirmed FDA, Wikidata
- Wikidata Q48851193trevogrumabConfirmed FDA, Wikidata
- NCI Thesaurus C152733TrevogrumabOne source FDA
- DrugBank DB15159One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 87T4327873 | TREVOGRUMAB | Confirmed FDA, Wikidata |
| Wikidata | Q48851193 | trevogrumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152733 | Trevogrumab | One source FDA |
| DrugBank | DB15159 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.